Coherus Oncology (CHRS) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Coherus Oncology (CHRS) over the last 11 years, with Q3 2025 value amounting to -$0.38.
- Coherus Oncology's EPS (Weighted Average and Diluted) rose 731.71% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.43, marking a year-over-year increase of 57638.89%. This contributed to the annual value of $0.25 for FY2024, which is 10981.24% up from last year.
- As of Q3 2025, Coherus Oncology's EPS (Weighted Average and Diluted) stood at -$0.38, which was up 731.71% from $2.57 recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's EPS (Weighted Average and Diluted) peaked at $2.57 during Q2 2025, and registered a low of -$2.37 during Q1 2021.
- For the 5-year period, Coherus Oncology's EPS (Weighted Average and Diluted) averaged around -$0.33, with its median value being -$0.49 (2021).
- As far as peak fluctuations go, Coherus Oncology's EPS (Weighted Average and Diluted) tumbled by 62320.22% in 2021, and later skyrocketed by 63541.67% in 2025.
- Coherus Oncology's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.61 in 2021, then fell by 25.41% to -$0.76 in 2022, then rose by 2.63% to -$0.74 in 2023, then soared by 332.79% to $1.72 in 2024, then crashed by 122.06% to -$0.38 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.38 for Q3 2025, versus $2.57 for Q2 2025 and -$0.49 for Q1 2025.